TEM logo

TEM
Tempus AI Inc

20,272
Mkt Cap
$8.38B
Volume
87,624.00
52W High
$104.32
52W Low
$41.73
PE Ratio
-27.16
TEM Fundamentals
Price
$46.66
Prev Close
$46.18
Open
$47.08
50D MA
$49.10
Beta
0.00
Avg. Volume
5.38M
EPS (Annual)
-$1.41
P/B
20.08
Rev/Employee
$334,681.32
$10,862.42
Loading...
Loading...
News
all
press releases
Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that 37 abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The event will take place May 29 - June 3...
News Placeholder
More News
News Placeholder
Tempus AI (TEM) Launches ArteraAI Prostate Test, The First Externally Developed Digital Pathology Algorithm
Tempus AI (TEM) Launches ArteraAI Prostate Test, The First Externally Developed Digital Pathology Algorithm...
News Placeholder
Hims & Hers Deepens Personalized Care Through Platform Expansion
HIMS broadens beyond telehealth, adding labs, new hormone programs and global expansion as it builds a personalized care platform.
News Placeholder
Tempus AI Expands Cancer Platform With Launch of ArteraAI Prostate Test For Metastatic Patients
TEM is integrating externally developed AI pathology into its ecosystem to improve risk prediction and personalize prostate cancer treatment decisions.
News Placeholder
Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts
Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts PR Newswire NEW YORK, May 19...
News Placeholder
HIMS Stock Dips 14.3% Since Q1 Earnings: Should You Still Hold or Sell?
Hims & Hers faces profit pressure in first-quarter 2026, though subscribers increase and a Novo Nordisk GLP-1 partnership broadens weight-loss care.
News Placeholder
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts
Tempus AI And Bristol Myers Squibb Expand AI-Driven Trial Design Efforts Across Oncology And Alzheimer's Programsread more...
News Placeholder
Here's Why Aristotle Core Equity Fund Bets on Tempus AI (TEM), a Healthcare Technology Company
Here's Why Aristotle Core Equity Fund Bets on Tempus AI (TEM), a Healthcare Technology Company...
News Placeholder
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This...
News Placeholder
Ark Invest Again Sells AMD, This Time As Stock Hits 52-Week High While Snapping Up Tempus AI And Circle
On Monday, Cathie Woods Ark Invest executed significant trades involving Advanced Micro Devices Inc. (NASDAQ:AMD), Tempus AI Iread more...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available